Global Statistics Representing Autoinjector Market Scenario
Global autoinjector market was valued at around USD 29,470.45 million in 2018 and is projected to continue growing at a CAGR of 14.4% during the forecast period 2019-2026.
Patient use autoinjectors for self-administering recommended dosage of drug as they are easy to use and do not require supervision of medical professionals. Among all the auto injections, ‘epinephrine auto-injectors’ are highly preferred for treating anaphylaxis since adrenaline auto-injectors are prescribed for the people who are at the high risk of severe allergic reactions. According to Food Allergy Research and Education, around 32 million Americans are suffering from food allergies and about 40% of children having food allergies. In the U.K., over 2 million people are diagnosed with food allergy. Moreover, about 65% of patients get hospitalized due to food hypersensitivity and 35% patient hospitalized due to foodborne disease.
Autoinjectors are expected to witness increasing demand in the market thanks to growing adoption of targeted therapy, increasing sensitivity to allergens, and easy drug administration. Moreover, autoinjectors come handy during emergency medical situation as well as when no one is around the patient who can administer the drug. Auto-injectors are likely to surge in the demand on account of rapidly growing prevalence of cardiovascular diseases across the globe. For instance, around 46% U.S. adults or 116.4 million people were diagnosed with hypertension in 2018.
Global autoinjector market is segmented by therapy, type, end-users, and regions.
Based on therapy, the autoinjector market is segmented into anaphylaxis, rheumatoid arthritis, psoriasis, migraine, cardiovascular disease, and other emergency conditions. Anaphylaxis reaction is expected to dominate the market with the growing number of people highly sensitive towards the allergens like dust, insect, and pollen among others. According to the American Academy of Allergy Asthma & Immunology, adverse drug reactions may affect up to 10% of the world’s population and about 20% of hospitalized patients.
Based on the type, the autoinjector market is segmented into disposable and reusable. Disposable autoinjectors segment is expected to hold major market share during the forecast period as they are easy to assemble and highly preferred to prevent spreading of infection.
On the basis of the end-users, the autoinjector market is segmented into hospitals & clinics and home care and diagnostic centers. Home care segment is expected to lead the market during the forecast period owing to their growing adoption by the geriatric population as most of the population receive treatment at home. According to the United Nations by 2050, one in six people would be over and above 65, and currently, the current rate is one in eleven.
Geographically, autoinjector market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).
North America is expected to dominate the global autoinjector market during the forecast period, owing to increasing prevalence of psoriasis, cardiovascular disease, and anaphylactic reaction. As per National Psoriasis Foundation, more than 8 million Americans are suffering from Psoriasis. Autoinjectors in psoriasis improve the challenges regarding the treatment such as injection anxiety and functional impairment. Autoinjectors can be used in cases of both moderate-to-severe plaque psoriasis. In the U.S., the demand is increasing at a very high pace that Mylan, top producer of Epipen, is unable to meet the market demand. This shortage is affecting the U.S., Canada, Australia, and the U.K.
In the U.S. over 610,000 people are dying from heart disease every year that is 1 in every 4 death is due to cardiovascular disease, Centre for Cardiovascular Disease. This can be attributed to growing, prevalence of obesity and diabetes, excessive smoking and alcohol consumption, and lack of physical activity. Among half of the Americans (47%) have at least one of the above mentioned risk factors.
Europe is the second leading region in the global autoinjector market, owing to increasing incidences of asthma and asthma attacks cases in the region. According to Asthma Organisation of the U.K., around 5.4 million people are receiving asthma treatment, and among them over 200,000 people have severe asthma. EpiPen auto-injector is used as a first aid treatment of anaphylaxis to avoid further complications and prevent seriousness of the condition. In the U.K, around 25 million students lose work or school each year due to Absenteeism. Absenteeism due to migraine cost around USD 2081 billion every year in the U.K. Single-use Alsuma auto-injector are easy to use and preferred for treating acute migraine attack as they are less painful and show minimum injection site reactions.
Asia Pacific is expected to grow at the highest CAGR during the forecast period as a result of rapidly expanding geriatric population being provided with home care or unable to visit the hospitals on a regular basis. LAMEA is expected to witness sluggish growth due to low penetration of healthcare services, poor infrastructure, minimum research and development activities in drug administration procedure, and high dependency on traditional method of administration.
Our Report Covers
Some of the key players in the global autoinjector market Biogen (U.S.), SHL Group (CHINA), BD (U.S.), Mylan N.V (Netherlands), Sanofi (U.S.), Pfizer Inc (U.S.), Ypsomed AG (Switzerland), Antares Pharma (U.S.), Novartis AG (Switzerland), and AbbVie Inc (U.S.)
Autoinjector market Segmentation
By End User